ArticlePloS one2018
A high mortality rate associated with multidrug-resistant Acinetobacter baumannii ST79 and ST25 carrying OXA-23 in a Brazilian intensive care unit.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Antibiotic Resistance and Biofilm Gene Distribution in Colistin-Resistant Acinetobacter baumannii.MicrobiologyOpen · 2026Article
- Review
- Comparative genomics reveals avian Acinetobacter baumannii as antimicrobial resistance reservoirs and bovine strains with elevated pathogenicity.Scientific reports · 2025Article
- Antimicrobial potential of compounds from the MMV pandemic response box and COVID box against carbapenem-resistant Acinetobacter baumannii.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Phylogenomic analysis of aquatic and clinical OXA-23-positiveOne health (Amsterdam, Netherlands) · 2025Article
- Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producingMicrobiology spectrum · 2025Article
- Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.npj antimicrobials and resistance · 2025Article
- A single-center analysis of clonal transmission of carbapenem-resistant Acinetobacter baumannii among intensive care unit patients during the COVID-19 pandemic.Scientific reports · 2024Article
- Molecular epidemiology of carbapenemase encoding genes inJAC-antimicrobial resistance · 2024Article
- Article
- Descriptive analysis of targeted carbapenemase genes and antibiotic susceptibility profiles among carbapenem-resistantMicrobiology spectrum · 2024Article
- Antimicrobial resistance genes harbored in invasiveFrontiers in cellular and infection microbiology · 2024Article
- Multiple host colonization and differential expansion of multidrug-resistant ST25-Acinetobacter baumannii clades.Scientific reports · 2023Article
- Risk factors for progression to bacteremia among patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia in the Intensive Care Unit.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Healthcare Equipment and Personnel Reservoirs of Carbapenem-ResistantMicroorganisms · 2023Article
- Molecular Typing and Resistance Profile ofAntibiotics (Basel, Switzerland) · 2023Article
- Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii.PLoS pathogens · 2023Article
- Molecular epidemiology of Acinetobacter baumannii complex causing invasive infections in Korean children during 2001-2020.Annals of clinical microbiology and antimicrobials · 2023Article
- Genomic characterization of an NDM-9-producingFrontiers in microbiology · 2023Article
- Genomic Analysis of Carbapenem-Resistant Acinetobacter baumannii Strains Recovered from Chilean Hospitals Reveals Lineages Specific to South America and Multiple Routes for Acquisition of Antibiotic Resistance Genes.Microbiology spectrum · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global spread of carbapenem-resistant Acinetobacter baumannii (A. baumannii) strains has restricted the therapeutic options available to treat infections due to this pathogen. Understanding the prevalence of such infections and the underlying genetic mechanisms of resistance may help in the implementation of adequate measures to control and prevent acquisition of nosocomial infections, especially in an intensive care unit setting. This study describes the molecular characteristics and risk factors associated with OXA-23-producing A. baumannii infections. A case-control study was undertaken from September/2013 to April/2015. Acquisition of OXA-23-producing A. baumannii was found to be associated with the use of nasogastric tubes, haemodialysis, and the use of cephalosporins. These isolates were only susceptible to amikacin, gentamicin, tigecycline, and colistin, and contained the ISAba1 insertion sequence upstream ofblaOXA-23 and blaOXA-51 genes. Twenty-six OXA-23-producing A. baumannii strains belonged to the ST79 (CC79) clonal group,and patients infected or colonised by these isolates had a higher mortality rate (34.6%). In conclusion, this study showed a dissemination of OXA-23-producing A. baumannii strains that was associated with several healthcare-related risk factors and high mortality rates among intensive care unit patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.